洞察

Vol.47, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

Between March 14 and 21, a total of 17 deals were signed globally, including two out-licensing agreements in the China biotech industry. Formosa Pharmaceuticals and Cipla finalized an out-licensing agreement for APP13007 (clobetasol propionate nanoparticle), an approved asset. Additionally, HiROand HallymUniversity Sacred Heart Hospital entered into a cooperation agreement for innovative drug development. Globally, 15 other deals were signed during the same period. The most significant transaction of the week was Sanofi’s acquisition of DR-0201, a Phase I asset, from Dren Bio., valued at $1.9 billion, with an upfront payment of $600 million. 2025年3月14-21日，全球医药市场共签署了17项资产授权和合作协议。中国市场共达成2项交易，均为出海交易。 台新药就已上市新药APP13007（丙酸氯倍他索纳米混悬滴眼液）与印度Cipla公司达成多区域授权合作协议。贺维斯特医药科技集团与韩国翰林大学圣心医院签署战略合作备忘，共同推动创新药物开发。 国际市场上，本周共签署了15项资产授权和合作协议。最大的一笔交易是Sanofi收购Dren Bio.临床一期资产DR-0201，首付款6亿美元，总金额19亿美

查看更多 →